公开(公告)号：US20220412994A1

公开(公告)日：2022-12-29

申请号：US17775217

申请日：2020-11-06

Applicant: Randox Laboratories Ltd

Inventor： Paul Innocenzi ,  Mark Ruddock ,  John Lamont ,  Peter Fitzgerald

IPC: G01N33/68

Abstract: Described is the use of GFAP as a marker of drug-induced cellular toxicity and depression.

公开(公告)号：US20220011311A1

公开(公告)日：2022-01-13

申请号：US17294358

申请日：2019-11-15

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  John Lamont ,  Stephen Fitzgerald ,  Kathleen Williamson

IPC: G01N33/574

Abstract: The present invention provides a method for detecting the presence or risk of bladder cancer in a female patient comprising the steps of detecting the presence of a panel of biomarkers in a sample isolated from a female patient, said panel of biomarkers comprising IL-13 and IL-12p70 and one or more biomarkers selected from BTA, Midkine, PAI-1/tPA, 8OHdG, CEA, CK18, Clusterin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-Dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9NGAL, MMP9TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglycerides and/or the concentration of albumin/microalbumin/protein and creatinine expressed as an albumin:creatinine ratio in a sample isolated from a female patient; and assessing the results and comparing them to a normal control wherein an elevated presence of the biomarker compared to a normal control indicates the presence or risk of cancer in the patient from whom the sample is isolated.

公开(公告)号：US20170089900A1

公开(公告)日：2017-03-30

申请号：US15304473

申请日：2015-04-02

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  Cherith Reid ,  John Lamont ,  Stephen Fitzgerald ,  Ricardo De Matos Simoes ,  Kathleen Williamson

IPC: G01N33/574 ,  G01N33/577 ,  G01N33/543

CPC classification number: G01N33/57407 ,  G01N33/543 ,  G01N33/57488 ,  G01N33/577 ,  G01N33/6869 ,  G01N2333/485 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.

公开(公告)号：US20240402176A1

公开(公告)日：2024-12-05

申请号：US18696817

申请日：2022-09-29

Applicant: RANDOX LABORATORIES LTD.

Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont

IPC: G01N33/574 ,  G01N33/543

Abstract: Haematuria is a considerable burden within primary and secondary care; too many haematuria patients are referred to secondary care for invasive and expensive investigations that could be managed in primary care. The current invention has identified biomarker combinations with utility for the diagnosis of bladder cancer in males. Using gender specific biomarker algorithms in combination with clinical risks that are associated with bladder cancer, would allow clinicians to better manage haematuria patients in primary care setting.

公开(公告)号：US20240345092A1

公开(公告)日：2024-10-17

申请号：US18682668

申请日：2022-08-10

Applicant: RANDOX LABORATORIES LTD.

Inventor： Stephen Peter Fitzgerald ,  Mark Ruddock ,  John Lamont ,  Declan McKenna

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N33/57488

Abstract: Single markers lack both sensitivity and specificity to stratify risk of PCa in patients who present with elevated tPSA and abnormal DRE. The novel combination of serum markers identified in this study could be employed to help triage patients into ‘low’ and ‘high’ risk categories, allowing general practitioners (GPs) to improve management of patients in primary care settings and potentially reducing the number of referrals for unnecessary, invasive, and costly treatments.

公开(公告)号：US10168331B2

公开(公告)日：2019-01-01

申请号：US15304473

申请日：2015-04-02

Applicant: Randox Laboratories Ltd.

Inventor： Mark Ruddock ,  Cherith Reid ,  John Lamont ,  Stephen Fitzgerald ,  Ricardo De Matos Simoes ,  Kathleen Williamson

IPC: G01N33/574 ,  G01N33/68 ,  G01N33/543 ,  G01N33/577

Abstract: The present invention provides a method and a solid state device for identifying the presence of urothelial cancer in a patient comprising assigning the subject to a sub-population according to smoking habits, measuring the level of each biomarker of a panel of biomarkers in one or more samples obtained from the subject; and correlating the measured levels of the panel of biomarkers with the likelihood of the subject having urothelial cancer such that the subject can be classified as having urothelial cancer or as being a control.